High BP and Home Monitoring Experience (HoME) Study

High Blood Pressure Clinical Trial

— HoME  

Official title:

Adoption and Effectiveness of a mHealth Intervention for Hypertension in Older Adults: a Pilot Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03650166
• Other study ID #: PRO18050328
• Status: Completed
• Phase: N/A
• Start date: September 21, 2018
• Est. completion date: August 30, 2019

Study information

• Verified date: October 2019
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

High blood pressure is a leading risk factor for cardiovascular and kidney disease, yet is uncontrolled in half of affected individuals, and specifically older adults. The investigators have developed an automated program for patient education and personalized assistance of systematic home BP self-monitoring. Reports are sent to primary care providers at regular intervals. This investigation will collect pilot data on feasibility and effectiveness in older adults with and without a caregiver.

Description:

Background. Hypertension is a highly prevalent condition and a primary cause of heart disease, kidney failure and cognitive decline. Hypertension is uncontrolled in nearly half of diagnosed adults in the US, with the lowest control rates among older adults (i.e., over 60 y/o). Uncontrolled hypertension is attributable to a mix of factors, most notably suboptimal self-management among patients and clinical inertia due to the reliance on limited BP measurement at office visits, which results in diagnostic uncertainty.

Home BP monitoring (HBPM) is a promising solution to catalyze patient engagement in self-management while offering clinicians reliable and up-to-date data, thereby improving clinical management. Home blood pressure monitoring (HBPM) is now widely recommended as an effective additional tool for improved hypertension management, however broad implementation has not occurred. The convenience of mobile phones has led to high and increasing ownership among all age groups, thus there is great potential to leverage mobile health (mHealth) applications to make HBPM easy, convenient, and even more helpful for both clinicians and patients.

Based upon extensive stakeholder input, the investigators' multidisciplinary team designed a comprehensive mobile phone supported HBPM system called MyBP. MyBP efficiently educates patients via professionally-developed videos and supports bi-weekly BP self-monitoring with recurring feedback using proactive, bidirectional automated texting. Prior pilot testing at three unique clinical sites with middle-aged adults (mean 50 y/o) suggests good usability and positive effects on self-management behaviors. High priority next steps are to: 1) test MyBP specifically with older adults (and caregivers) to fully understand their unique experiences in regards to HBPM via mobile phone, and 2) explore how best to share MyBP data with primary care providers (PCPs). Therefore, the aims of this study are to:

1. Collect pilot data on longitudinal usage of MyBP and BP reduction over 6-9 months within an older adult population.

2. Examine factors influencing adoption and sustained use of MyBP and any associated BP reduction.

3. Identify potentially unique user experiences among older adults with increasing frailty and in those who rely on caregivers.

Methods. Forty-eight older adults (60-85 y/o) with uncontrolled hypertension will be randomized 2:1 to active intervention (MyBP plus a home BP cuff) or usual care (home BP cuff alone) for 6-9 months. Participants will be recruited from UPMC primary care practices. For participants for whom a caregiver has primary responsibility for hypertension-related health behaviors, MyBP will be used by the caregiver. Gait speed will be measured to assess frailty. At baseline and study completion, standardized measurement of home BP will be conducted. Patients and caregivers will complete questionnaires and a semi-structured audio-recorded interview to assess factors associated with MyBP utility and engagement, BP self-management and BP lowering.

Future use of data. Findings will be used to refine the MyBP system design to best fit the target audience and as "preliminary evidence" in an NIH R01 proposal to test in a randomized clinical trial of MyBP in the primary care setting among both mid-life and older adults with uncontrolled hypertension.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 62
• Est. completion date: August 30, 2019
• Est. primary completion date: August 2, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of High blood pressure

• Office systolic BP reading 150 mm Hg or higher

• Owns a cell phone with unlimited texting

Exclusion Criteria:

• Arm circumference > 45 cm

• Dementia

Related Conditions & MeSH terms

• High Blood Pressure
• Hypertension

Intervention

Other:
• MyBP
This program includes online video high BP education and longitudinal, personalized assistance of home BP self-monitoring.
• Personal BP monitor
Battery-powered BP monitor for personal use

Locations

Country	Name	City	State
United States	University of Pittsburgh	Pittsburgh	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in systolic BP from baseline to trial completion	Seated BP will be measured in duplicate during each of two baseline assessments (4 total readings) and again in duplicate at each of two assessments at trial completion (4 readings). The primary outcome is the change in average systolic BP from baseline to follow-up. This will be calculated as the average systolic BP at follow-up minus the average systolic BP at baseline. The change in BP in two intervention groups will be compared.	5-8 months (Trial duration is not identical across participants but is anticipated to be between 5 and 8 months.)
Secondary	Change in participants' hypertension self-efficacy (confidence in ability to fully understand and manage his or her high BP)	Hypertension self-efficacy will be assessed at baseline and trial completion with this question: Please rate your confidence in your ability to fully understand and manage your high BP. [No confidence; A little confidence; Some confidence; High confidence; Very high confidence.] Answers are scored 1-5. Change in score will be compared across the two intervention groups.	5-8 months
Secondary	Change in systolic BP from baseline to trial mid-point	Seated BP will be measured in duplicate during each of two baseline assessments (4 total readings) and also during two assessments at trial mid-point (4 readings). This secondary outcome is the change in average systolic BP from baseline to trial mid-point. This will be calculated as the average systolic BP at mid-point minus the average systolic BP at baseline. The change in BP in two intervention groups will be compared.	Approximately 14 weeks